S&P 500   4,145.19
DOW   32,803.47
QQQ   321.75
China July exports rise, with trade surplus at record-high
pixel
Shift in war's front seen as ships cleared to leave Ukraine
Demand for grocery delivery cools as food costs rise
What's in Democrats' big bill? Climate, health care, savings
Transit woes mount for Boston's beleaguered subway riders
Dems push Biden climate, health priorities toward Senate OK
Shift in war's front seen as grain leaves Ukraine; plant hit
S&P 500   4,145.19
DOW   32,803.47
QQQ   321.75
China July exports rise, with trade surplus at record-high
pixel
Shift in war's front seen as ships cleared to leave Ukraine
Demand for grocery delivery cools as food costs rise
What's in Democrats' big bill? Climate, health care, savings
Transit woes mount for Boston's beleaguered subway riders
Dems push Biden climate, health priorities toward Senate OK
Shift in war's front seen as grain leaves Ukraine; plant hit
S&P 500   4,145.19
DOW   32,803.47
QQQ   321.75
China July exports rise, with trade surplus at record-high
pixel
Shift in war's front seen as ships cleared to leave Ukraine
Demand for grocery delivery cools as food costs rise
What's in Democrats' big bill? Climate, health care, savings
Transit woes mount for Boston's beleaguered subway riders
Dems push Biden climate, health priorities toward Senate OK
Shift in war's front seen as grain leaves Ukraine; plant hit
S&P 500   4,145.19
DOW   32,803.47
QQQ   321.75
China July exports rise, with trade surplus at record-high
pixel
Shift in war's front seen as ships cleared to leave Ukraine
Demand for grocery delivery cools as food costs rise
What's in Democrats' big bill? Climate, health care, savings
Transit woes mount for Boston's beleaguered subway riders
Dems push Biden climate, health priorities toward Senate OK
Shift in war's front seen as grain leaves Ukraine; plant hit

Biotech Stocks List

Compare biotech stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. AMGN, BIIB, GILD, ILMN, VRTX, REGN, MRNA, IQV, MTD, BNTX).

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Amgen Inc. stock logo
AMGN
Amgen
$246.25
-0.3%
$245.14
$198.64
$258.45
$131.55B0.562.40 million shs2.72 million shs
Biogen Inc. stock logo
BIIB
Biogen
$218.20
+0.4%
$208.10
$187.16
$351.86
$31.66B0.4948,781 shs670,487 shs
BioNTech SE stock logo
BNTX
BioNTech
$183.11
+1.5%
$154.71
$117.08
$464.00
$44.50B-0.08790,167 shs1.58 million shs
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
$61.09
-1.3%
$61.55
$57.17
$74.12
$76.63B0.346.11 million shs6.04 million shs
Illumina, Inc. stock logo
ILMN
Illumina
$223.77
-0.7%
$204.20
$173.45
$526.00
$35.15B1.151.10 million shs747,913 shs
IQVIA Holdings Inc. stock logo
IQV
IQVIA
$234.74
+0.2%
$216.94
$194.67
$285.61
$43.78B1.32982,322 shs678,106 shs
Moderna, Inc. stock logo
MRNA
Moderna
$186.84
-3.8%
$152.33
$115.61
$497.49
$74.32B1.614.71 million shs5.43 million shs
Mettler-Toledo International Inc. stock logo
MTD
Mettler-Toledo International
$1,347.72
+0.1%
$1,215.14
$1,082.78
$1,714.75
$30.33B1.12122,911 shs75,956 shs
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
$613.61
-0.2%
$598.47
$538.01
$747.42
$66.60B0.29564,864 shs566,774 shs
Vertex Pharmaceuticals Incorporated stock logo
VRTX
Vertex Pharmaceuticals
$288.03
+4.8%
$277.50
$176.36
$296.84
$73.67B0.451.40 million shs2.40 million shs

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Amgen Inc. stock logo
AMGN
Amgen
0.00%-0.49%-0.47%+4.12%+7.86%
Biogen Inc. stock logo
BIIB
Biogen
0.00%+1.46%+0.11%+12.70%-35.46%
BioNTech SE stock logo
BNTX
BioNTech
0.00%+10.87%+9.01%+34.47%-55.82%
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
0.00%+2.24%-2.60%-0.15%-11.77%
Illumina, Inc. stock logo
ILMN
Illumina
0.00%+3.27%+10.67%-10.15%-55.65%
IQVIA Holdings Inc. stock logo
IQV
IQVIA
0.00%-2.30%+7.26%+9.78%-6.05%
Moderna, Inc. stock logo
MRNA
Moderna
0.00%+13.86%+8.38%+39.02%-55.41%
Mettler-Toledo International Inc. stock logo
MTD
Mettler-Toledo International
0.00%-0.15%+11.63%+2.42%-11.06%
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
0.00%+5.49%+1.01%-1.52%+5.62%
Vertex Pharmaceuticals Incorporated stock logo
VRTX
Vertex Pharmaceuticals
0.00%+2.72%-2.09%+13.43%+44.31%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Amgen Inc. stock logo
AMGN
Amgen
2.32 of 5 Stars
1.12.04.23.92.32.52.5
Biogen Inc. stock logo
BIIB
Biogen
2.69 of 5 Stars
3.35.00.03.82.91.71.9
BioNTech SE stock logo
BNTX
BioNTech
2.29 of 5 Stars
4.33.00.00.02.30.01.3
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
2.96 of 5 Stars
3.13.03.34.13.21.72.5
Illumina, Inc. stock logo
ILMN
Illumina
3.01 of 5 Stars
3.15.00.04.22.82.53.1
IQVIA Holdings Inc. stock logo
IQV
IQVIA
2.40 of 5 Stars
2.53.00.04.62.41.72.5
Moderna, Inc. stock logo
MRNA
Moderna
2.31 of 5 Stars
2.13.00.04.63.43.31.3
Mettler-Toledo International Inc. stock logo
MTD
Mettler-Toledo International
1.91 of 5 Stars
1.03.00.03.32.32.52.5
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
2.48 of 5 Stars
3.22.00.03.92.92.51.9
Vertex Pharmaceuticals Incorporated stock logo
VRTX
Vertex Pharmaceuticals
2.38 of 5 Stars
2.33.00.03.32.92.52.5

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Amgen Inc. stock logo
AMGN
Amgen
2.20
Hold$250.001.52% Upside
Biogen Inc. stock logo
BIIB
Biogen
2.52
Moderate Buy$252.4415.69% Upside
BioNTech SE stock logo
BNTX
BioNTech
2.50
Moderate Buy$243.4232.93% Upside
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
2.21
Hold$72.0717.97% Upside
Illumina, Inc. stock logo
ILMN
Illumina
2.22
Hold$384.4571.81% Upside
IQVIA Holdings Inc. stock logo
IQV
IQVIA
2.94
Moderate Buy$274.4416.91% Upside
Moderna, Inc. stock logo
MRNA
Moderna
2.18
Hold$226.9221.45% Upside
Mettler-Toledo International Inc. stock logo
MTD
Mettler-Toledo International
2.00
Hold$1,298.25-3.67% Downside
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
2.47
Hold$697.8513.73% Upside
Vertex Pharmaceuticals Incorporated stock logo
VRTX
Vertex Pharmaceuticals
2.65
Moderate Buy$289.900.65% Upside

Current Analyst Ratings

Latest Biotech Stocks Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/5/2022
Amgen Inc. stock logo
AMGN
Amgen
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight$260.00 ➝ $265.00
8/5/2022
Amgen Inc. stock logo
AMGN
Amgen
Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price Target$224.00 ➝ $236.00
8/5/2022
Vertex Pharmaceuticals Incorporated stock logo
VRTX
Vertex Pharmaceuticals
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy$275.00 ➝ $300.00
8/5/2022
Vertex Pharmaceuticals Incorporated stock logo
VRTX
Vertex Pharmaceuticals
Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight$291.00 ➝ $307.00
8/4/2022
Moderna, Inc. stock logo
MRNA
Moderna
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetEqual Weight$199.00 ➝ $197.00
8/4/2022
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
BMO Capital Markets
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform$757.00 ➝ $788.00
8/4/2022
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetEqual Weight$619.00 ➝ $625.00
8/2/2022
Biogen Inc. stock logo
BIIB
Biogen
Robert W. Baird
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingNeutral ➝ Neutral$224.00
8/1/2022
Moderna, Inc. stock logo
MRNA
Moderna
SVB Leerink
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetUnderperform$70.00 ➝ $77.00
8/1/2022
Mettler-Toledo International Inc. stock logo
MTD
Mettler-Toledo International
Robert W. Baird
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetNeutral$1,369.00 ➝ $1,406.00
7/29/2022
BioNTech SE stock logo
BNTX
BioNTech
SVB Leerink
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform$223.00 ➝ $224.00
(Data available from 8/7/2019 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Amgen Inc. stock logo
AMGN
Amgen
$25.98B5.06$23.63 per share10.42$12.00 per share20.52
Biogen Inc. stock logo
BIIB
Biogen
$10.98B2.88$27.17 per share8.03$81.75 per share2.67
BioNTech SE stock logo
BNTX
BioNTech
$22.45B1.98$50.58 per share3.62$58.02 per share3.16
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
$27.31B2.81$8.96 per share6.82$16.12 per share3.79
Illumina, Inc. stock logo
ILMN
Illumina
$4.53B7.77$7.52 per share29.77$68.71 per share3.26
IQVIA Holdings Inc. stock logo
IQV
IQVIA
$13.87B3.16$15.21 per share15.43$28.70 per share8.18
Moderna, Inc. stock logo
MRNA
Moderna
$18.47B4.02$30.78 per share6.07$45.22 per share4.13
Mettler-Toledo International Inc. stock logo
MTD
Mettler-Toledo International
$3.72B8.16$39.72 per share33.93$0.32 per share4,211.63
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
$16.07B4.14$80.84 per share7.59$190.60 per share3.22
Vertex Pharmaceuticals Incorporated stock logo
VRTX
Vertex Pharmaceuticals
$7.57B9.73$12.63 per share22.80$39.72 per share7.25

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Amgen Inc. stock logo
AMGN
Amgen
$5.89B$11.8020.8712.952.0424.92%188.78%16.13%11/1/2022 (Estimated)
Biogen Inc. stock logo
BIIB
Biogen
$1.56B$14.0215.5613.441.0119.36%22.36%10.42%10/19/2022 (Estimated)
BioNTech SE stock logo
BNTX
BioNTech
$12.18B$57.453.1910.05N/A55.13%122.24%86.07%8/8/2022 (Confirmed)
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
$6.23B$3.2818.639.400.6315.03%42.92%13.59%10/27/2022 (Estimated)
Illumina, Inc. stock logo
ILMN
Illumina
$762M$4.6048.6541.901.7515.04%8.37%5.78%8/11/2022 (Confirmed)
IQVIA Holdings Inc. stock logo
IQV
IQVIA
$966M$5.9939.1921.922.148.21%30.21%7.13%10/20/2022 (Estimated)
Moderna, Inc. stock logo
MRNA
Moderna
$12.20B$32.815.6923.741.0561.12%94.76%56.65%11/3/2022 (Estimated)
Mettler-Toledo International Inc. stock logo
MTD
Mettler-Toledo International
$768.98M$35.4937.9731.793.3221.23%799.34%25.53%11/3/2022 (Estimated)
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
$8.08B$50.1012.2515.041.8839.97%36.17%27.00%11/3/2022 (Estimated)
Vertex Pharmaceuticals Incorporated stock logo
VRTX
Vertex Pharmaceuticals
$2.34B$12.3723.2821.412.1238.26%32.56%24.67%11/1/2022 (Estimated)

Latest Biotech Stocks Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/11/2022N/A
Illumina, Inc. stock logo
ILMN
Illumina
$0.63N/A-$0.63N/AN/AN/A  
8/8/2022N/A
BioNTech SE stock logo
BNTX
BioNTech
$6.66N/A-$6.66N/AN/AN/A  
8/4/2022Q2
Amgen Inc. stock logo
AMGN
Amgen
$4.40$4.65+$0.25N/A$6.53 billion$6.59 billion    
8/4/2022Q2
Vertex Pharmaceuticals Incorporated stock logo
VRTX
Vertex Pharmaceuticals
$3.12$3.60+$0.48N/A$2.13 billion$2.20 billion      
8/3/2022Q2
Moderna, Inc. stock logo
MRNA
Moderna
$4.73$5.24+$0.51N/A$3.95 billion$4.73 billion    
8/3/2022Q2
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
$9.94$9.77-$0.17N/A$2.80 billion$2.86 billion    
7/29/2022N/A
Mettler-Toledo International Inc. stock logo
MTD
Mettler-Toledo International
$8.78$9.39+$0.61N/A$951.81 million$978.39 million      
7/21/2022Q2 22
IQVIA Holdings Inc. stock logo
IQV
IQVIA
$2.22$2.44+$0.22N/A$3.49 billion$3.54 billion      
7/20/2022Q2 22
Biogen Inc. stock logo
BIIB
Biogen
$4.09$5.25+$1.16N/A$2.48 billion$2.59 billion      
5/9/2022Q1 2022
BioNTech SE stock logo
BNTX
BioNTech
$9.14$15.98+$6.84$15.98$4.50 billion$6.37 billion    

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Amgen Inc. stock logo
AMGN
Amgen
$7.763.15%N/A65.76%11 Years
Biogen Inc. stock logo
BIIB
Biogen
N/AN/AN/AN/AN/A
BioNTech SE stock logo
BNTX
BioNTech
N/AN/AN/AN/AN/A
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
$2.924.78%N/A89.02%7 Years
Illumina, Inc. stock logo
ILMN
Illumina
N/AN/AN/AN/AN/A
IQVIA Holdings Inc. stock logo
IQV
IQVIA
N/AN/AN/AN/AN/A
Moderna, Inc. stock logo
MRNA
Moderna
N/AN/AN/AN/AN/A
Mettler-Toledo International Inc. stock logo
MTD
Mettler-Toledo International
N/AN/AN/AN/AN/A
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
N/AN/AN/AN/AN/A
Vertex Pharmaceuticals Incorporated stock logo
VRTX
Vertex Pharmaceuticals
N/AN/AN/AN/AN/A

Latest Biotech Stocks Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
8/2/2022
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
quarterly$0.734.85%9/14/20229/15/20229/29/2022
8/3/2022
Amgen Inc. stock logo
AMGN
Amgen
quarterly$1.943.14%8/17/20228/18/20229/8/2022
(Data available from 1/1/2013 forward)

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Amgen Inc. stock logo
AMGN
Amgen
39.31
1.44
1.09
Biogen Inc. stock logo
BIIB
Biogen
0.53
1.94
1.68
BioNTech SE stock logo
BNTX
BioNTech
0.01
5.05
4.93
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
1.31
1.49
1.30
Illumina, Inc. stock logo
ILMN
Illumina
0.11
1.85
1.54
IQVIA Holdings Inc. stock logo
IQV
IQVIA
2.36
0.96
0.96
Moderna, Inc. stock logo
MRNA
Moderna
0.04
1.99
1.56
Mettler-Toledo International Inc. stock logo
MTD
Mettler-Toledo International
250.82
1.18
0.77
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
0.13
5.12
4.09
Vertex Pharmaceuticals Incorporated stock logo
VRTX
Vertex Pharmaceuticals
0.05
4.75
4.60

Ownership

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Amgen Inc. stock logo
AMGN
Amgen
24,200534.20 million531.74 millionOptionable
Biogen Inc. stock logo
BIIB
Biogen
9,610145.11 million144.33 millionOptionable
BioNTech SE stock logo
BNTX
BioNTech
3,082243.02 millionN/ANot Optionable
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
14,4001.25 billion1.25 billionOptionable
Illumina, Inc. stock logo
ILMN
Illumina
9,150157.10 million156.90 millionOptionable
IQVIA Holdings Inc. stock logo
IQV
IQVIA
79,000186.51 million184.08 millionOptionable
Moderna, Inc. stock logo
MRNA
Moderna
2,700397.76 million328.95 millionOptionable
Mettler-Toledo International Inc. stock logo
MTD
Mettler-Toledo International
17,80022.51 million21.88 millionOptionable
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
10,368108.54 million98.78 millionOptionable
Vertex Pharmaceuticals Incorporated stock logo
VRTX
Vertex Pharmaceuticals
3,900255.76 million254.73 millionOptionable

Biotech Stocks Headlines

SourceHeadline
$1000 Invested In Vertex Pharmaceuticals 10 Years Ago Would Be Worth This Much Today$1000 Invested In Vertex Pharmaceuticals 10 Years Ago Would Be Worth This Much Today
msn.com - August 7 at 10:37 AM
Vertex Makes Bullish Move On Earnings, Leading 5 Stocks To WatchVertex Makes Bullish Move On Earnings, Leading 5 Stocks To Watch
finance.yahoo.com - August 6 at 9:37 AM
Vertex Pharmaceuticals (NASDAQ:VRTX) Announces Quarterly  Earnings Results, Beats Expectations By $0.48 EPSVertex Pharmaceuticals (NASDAQ:VRTX) Announces Quarterly Earnings Results, Beats Expectations By $0.48 EPS
marketbeat.com - August 5 at 5:49 PM
Why Vertex Pharmaceuticals Stock Was Soaring TodayWhy Vertex Pharmaceuticals Stock Was Soaring Today
fool.com - August 5 at 5:45 PM
Vertex (VRTX) Beats on Q2 Earnings, Ups 2022 Sales GuidanceVertex (VRTX) Beats on Q2 Earnings, Ups 2022 Sales Guidance
nasdaq.com - August 5 at 1:34 PM
Vertex Raises 2022 Outlook As Powerhouse Trikafta Drives Quarterly BeatVertex Raises 2022 Outlook As Powerhouse Trikafta Drives Quarterly Beat
finance.yahoo.com - August 5 at 1:34 PM
Vertex Pharmaceuticals (NASDAQ:VRTX) PT Raised to $300.00 at HC WainwrightVertex Pharmaceuticals (NASDAQ:VRTX) PT Raised to $300.00 at HC Wainwright
marketbeat.com - August 5 at 10:45 AM
Vertex Pharmaceuticals (VRTX) Q2 2022 Earnings Call TranscriptVertex Pharmaceuticals (VRTX) Q2 2022 Earnings Call Transcript
fool.com - August 5 at 5:34 AM
Vertex Reports Second Quarter 2022 Financial ResultsVertex Reports Second Quarter 2022 Financial Results
apnews.com - August 5 at 2:04 AM
Vertex Pharmaceuticals Lifts FY22 Product Revenue OutlookVertex Pharmaceuticals Lifts FY22 Product Revenue Outlook
markets.businessinsider.com - August 4 at 8:55 PM
Vertex Pharmaceuticals Inc. Reveals Rise In Q2 Bottom LineVertex Pharmaceuticals Inc. Reveals Rise In Q2 Bottom Line
markets.businessinsider.com - August 4 at 8:55 PM
Vertex Pharmaceuticals (VRTX) Surpasses Q2 Earnings and Revenue EstimatesVertex Pharmaceuticals (VRTX) Surpasses Q2 Earnings and Revenue Estimates
finance.yahoo.com - August 4 at 8:55 PM
Vertex Pharmaceuticals, Inc. (VRTX) CEO Reshma Kewalramani on Q2 2022 Results - Earnings Call TranscriptVertex Pharmaceuticals, Inc. (VRTX) CEO Reshma Kewalramani on Q2 2022 Results - Earnings Call Transcript
seekingalpha.com - August 4 at 8:55 PM
Vertex Pharmaceuticals Incorporated 2022 Q2 - Results - Earnings Call PresentationVertex Pharmaceuticals Incorporated 2022 Q2 - Results - Earnings Call Presentation
seekingalpha.com - August 4 at 8:51 PM
12 Best Healthcare Stocks To Buy Now12 Best Healthcare Stocks To Buy Now
finance.yahoo.com - August 4 at 3:54 PM
Sangeeta N. Bhatia Sells 621 Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) StockSangeeta N. Bhatia Sells 621 Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Stock
americanbankingnews.com - August 4 at 5:16 AM
Will Vertex Pharmaceuticals Q2 results bring positive surprise?Will Vertex Pharmaceuticals Q2 results bring positive surprise?
seekingalpha.com - August 3 at 3:29 PM
Dow Jones Futures Drop As Pelosi Heads To Taiwan; Uber Surges On Strong SalesDow Jones Futures Drop As Pelosi Heads To Taiwan; Uber Surges On Strong Sales
finance.yahoo.com - August 2 at 8:34 AM
Where Will CRISPR Therapeutics Be in 1 Year?Where Will CRISPR Therapeutics Be in 1 Year?
finance.yahoo.com - July 31 at 1:13 PM
My Top Stock to Buy If Were in a RecessionMy Top Stock to Buy If We're in a Recession
finance.yahoo.com - July 31 at 8:13 AM
Piper Sandler Boosts Vertex Pharmaceuticals (NASDAQ:VRTX) Price Target to $256.00Piper Sandler Boosts Vertex Pharmaceuticals (NASDAQ:VRTX) Price Target to $256.00
americanbankingnews.com - July 29 at 4:08 AM
Insider Selling: Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Chairman Sells 132,079 Shares of StockInsider Selling: Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Chairman Sells 132,079 Shares of Stock
americanbankingnews.com - July 28 at 5:48 AM
Vertex Pharmaceuticals (NASDAQ:VRTX) Price Target Raised to $256.00Vertex Pharmaceuticals (NASDAQ:VRTX) Price Target Raised to $256.00
marketbeat.com - July 26 at 7:41 AM
3 Winning Evergreen Stocks to Buy and Hold for the Next 25 Years3 Winning Evergreen Stocks to Buy and Hold for the Next 25 Years
finance.yahoo.com - July 26 at 7:32 AM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

All Headlines

Company Descriptions

Amgen logo

Amgen

NASDAQ:AMGN
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization. It also markets Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. It has collaboration agreements with Novartis Pharma AG; UCB; Bayer HealthCare LLC; BeiGene, Ltd.; Eli Lilly and Company; Datos Health; and Verastem, Inc. to evaluate VS-6766 in combination with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer. It has an agreement with Kyowa Kirin Co., Ltd. to jointly develop and commercialize KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis and other autoimmune diseases; and research and development collaboration with Neumora Therapeutics, Inc. and Plexium, Inc. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.
Biogen logo

Biogen

NASDAQ:BIIB
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; ADUHELM for the treatment of Alzheimer's disease; IMRALDI, an adalimumab biosimilar referencing HUMIRA; and FLIXABI, an infliximab biosimilar referencing REMICADE. In addition, the company offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; and OCREVUS for treating relapsing MS and primary progressive MS; and other anti-CD20 therapies. Further, it develops BIIB135, BIIB061, BIIB091, and BIIB107 for MS and neuroimmunology; Aducanumab, Lecanemab, BIIB076, and BIIB080 to treat Alzheimer's disease and dementia; BIIB067, BIIB078, BIIB105, BIIB100, and BIIB110 to treat neuromuscular disorders; BIIB124, BIIB094, BIIB118, BIIB101, and BIIB122 for treating Parkinson's disease and movement disorders; BIIB125 and BIIB104 for treating neuropsychiatry; Dapirolizumab pegol and BIIB059 to treat immunology related diseases; BIIB093 and BIIB131 to treat acute neurology; BIIB074 for neuropathic pain; and BYOOVIZ, BIIB800, and SB15 biosimilars, which are under various stages of development. The company has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc. Biogen Inc. was founded in 1978 and is headquartered in Cambridge, Massachusetts.
BioNTech logo

BioNTech

NASDAQ:BNTX
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV+ head and neck cancers; BNT114 that is in Phase I clinical trial for triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, a preclinical stage product for non-small cell lung cancer. It also develops neoantigen specific immunotherapies, such as Autogene cevumeran (BNT122), which is in Phase II clinical trial for first-line melanoma, as well as in Phase 1a/1b clinical trial to treat multiple solid tumors; mRNA intratumoral immunotherapy comprising SAR441000 that is in Phase I clinical trial for solid tumors; and BNT141 and BNT142 that are in Phase I clinical trial to treat multiple solid tumors. In addition, the company develops RiboCytokines, which include BNT151, BNT152, and BNT153 to treat solid tumors; chimeric antigen receptor T cell immunotherapies, such as BNT211 to treat multiple solid tumors, and BNT221 for other cancers; and checkpoint immunomodulators consisting of GEN1046 and GEN1042, which are in Phase I/II clinical trial to treat solid tumors. Further, it develops BNT321, an IgG1 monoclonal antibody in Phase II clinical trial for pancreatic cancer; BNT411, a small molecule immunomodulator product candidate for solid tumors; prophylactic vaccine for COVID-19 and Influenza; and infectious disease immunotherapies and rare disease protein replacement therapies. The company has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd.; and Regeneron Pharmaceuticals, Inc. BioNTech SE was incorporated in 2008 and is headquartered in Mainz, Germany.
Gilead Sciences logo

Gilead Sciences

NASDAQ:GILD
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of hematology, oncology, and cell therapy patients. In addition, the company provides Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; Ranexa, an oral formulation for the treatment of chronic angina; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. Gilead Sciences, Inc. has collaboration agreements with Arcus Biosciences, Inc.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Tango Therapeutics, Inc.; Jounce Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Gadeta B.V.; Bristol-Myers Squibb Company; Dragonfly Therapeutics, Inc.; and Merck & Co, Inc. The company was incorporated in 1987 and is headquartered in Foster City, California.
Illumina logo

Illumina

NASDAQ:ILMN
Illumina, Inc. provides sequencing and array-based solutions for genetic and genomic analysis. Its products and services serve customers in a range of markets enabling the adoption of genomic solutions in research and clinical settings for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. The company provides instruments and consumables used in genetic analysis; and genotyping and sequencing services, instrument service contracts, and development and licensing agreements, as well as cancer detection testing services. Its customers include genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. The company markets and distributes its products directly to customers in North America, Europe, Latin America, and the Asia-Pacific region, as well as sells through life-science distributors in various markets within Europe, the Asia-Pacific region, Latin America, the Middle East, and Africa. The company was incorporated in 1998 and is based in San Diego, California.
IQVIA logo

IQVIA

NYSE:IQV
IQVIA Holdings Inc. provides advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment offers a range of cloud-based applications and related implementation services; real world solutions that enable life sciences and provider customers to generate and disseminate evidence, which informs health care decision making and improves patients' outcomes; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services. This segment also provides country level performance metrics related to sales of pharmaceutical products, prescribing trends, medical treatment, and promotional activity across various channels, including retail, hospital, and mail order; and measurement of sales or prescribing activity at the regional, zip code, and individual prescriber level. The Research & Development Solutions segment offers project management and clinical monitoring; clinical trial support; virtual trials; and strategic planning and design services, as well as central laboratory, genomic, bioanalytical, ADME, discovery, and vaccine and biomarker laboratory services. The Contract Sales & Medical Solutions segment provides health care provider and patient engagement services, and scientific strategy and medical affairs services. It serves pharmaceutical, biotechnology, device and diagnostic, and consumer health companies. The company has a strategic collaboration with HealthCore, Inc. The company was formerly known as Quintiles IMS Holdings, Inc. and changed its name to IQVIA Holdings Inc. in November 2017. IQVIA Holdings Inc. was founded in 1982 and is headquartered in Durham, North Carolina.
Moderna logo

Moderna

NASDAQ:MRNA
Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, flu, respiratory syncytial virus, Endemic HCoV, and hMPV+PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, human immunodeficiency virus, herpes simplex virus, and varicella-zoster virus vaccines; and public health vaccines consists of Zika and Nipah vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; localized regenerative, systemic intracellular, and inhaled pulmonary therapeutics. It has strategic alliances with AstraZeneca PLC; Merck & Co., Inc.; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Carisma Therapeutics, Inc.; Metagenomi, Inc.; the Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation, as well as a collaboration and license agreement with Chiesi Farmaceutici S.P.A. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.
Mettler-Toledo International logo

Mettler-Toledo International

NYSE:MTD
Mettler-Toledo International Inc. engages in the manufacture and supply of precision instruments and services worldwide. It operates in five segments: U.S. Operations, Swiss Operations, Western European Operations, Chinese Operations, and Other. The company's laboratory instruments include laboratory balances, liquid pipetting solutions, automated laboratory reactors, titrators, pH meters, process analytics sensors and analyzer technologies, physical value analyzers, thermal analysis systems, and other analytical instruments; and LabX, a laboratory software platform to manage and analyze data generated from its instruments. Its industrial instruments comprise industrial weighing instruments and related terminals, automatic dimensional measurement and data capture solutions, vehicle scale systems, industrial software, metal detection, x-ray, checkweighing, camera-based imaging equipment, track-and-trace solutions, and product inspection systems. The company's retail weighing solutions consist of networked scales and software, stand-alone scales, and automated packaging and labeling solutions for handling fresh goods. It serves the life science industry, independent research organizations, and testing labs; food and beverage manufacturers; food retailers; chemical, specialty chemical, and cosmetics companies; food retailers; transportation and logistics, metals, and electronics industries; and the academic community through its direct sales force and indirect distribution channels. The company was incorporated in 1991 and is based in Columbus, Ohio.
Regeneron Pharmaceuticals logo

Regeneron Pharmaceuticals

NASDAQ:REGN
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma;Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration and license agreements with Sanofi; Bayer; Teva Pharmaceutical Industries Ltd.; Mitsubishi Tanabe Pharma Corporation; Alnylam Pharmaceuticals, Inc.; Roche Pharmaceuticals; and Kiniksa Pharmaceuticals, Ltd., as well as has an agreement with the U.S. Department of Health and Human Services, as well as with Zai Lab Limited; Intellia Therapeutics, Inc.; Biomedical Advanced Research Development Authority; and AstraZeneca PLC. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.
Vertex Pharmaceuticals logo

Vertex Pharmaceuticals

NASDAQ:VRTX
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAFTA for the treatment of patients with CF 6 years of age or older who have at least one F508del mutation. Its pipeline includes VX-864 for the treatment of AAT deficiency, which is in Phase 2 clinical trial; VX-147 for the treatment of APOL1-mediated focal segmental glomerulosclerosis, or FSGS, and other serious kidney diseases which is in Phase 2 clinical trial; VX- 880, treatment for Type 1 Diabetes which is in Phase 1/2 clinical trial; VX-548, a NaV1.8 inhibitor for treatments of acute, neuropathic, musculoskeletal pain which is in Phase 2 clinical trial; and CTX001 for the treatment severe SCD and TDT which is in Phase 3 clinical trial. The company sells its products primarily to specialty pharmacy and specialty distributors in the United States, as well as specialty distributors and retail chains, and hospitals and clinics internationally. It has collaborations with Affinia Therapeutics, Inc.; Arbor Biotechnologies, Inc.; CRISPR Therapeutics AG.; Kymera Therapeutics, Inc.; Mammoth Biosciences, Inc.; Moderna, Inc.; Obsidian Therapeutics, Inc.; and Skyhawk Therapeutics, Inc.; as well as Ribometrix, Inc.; Genomics plc; Merck KGaA; Darmstadt, Germany, and X-Chem, Inc. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.